
About Rhythm Pharmaceuticals
Rhythm Pharmaceuticals is a publicly listed company based in Boston (United States) founded in 2010. Rhythm Pharmaceuticals has raised $84 million across 9 funding rounds from investors including HHS, Ipsen and Orbimed. The company has 283 employees. Rhythm Pharmaceuticals has completed 1 acquisition, including Xinvento. Its chief executive, as recorded, is David Meeker. Its website rhythmtx.com draws about 31 thousand monthly visits. Rhythm Pharmaceuticals offers products and services including IMCIVREE and Clinical Trials. Its focus areas include Life Sciences, Metabolic Diseases, Drugs and Rare Diseases. Its legal entity is Rhythm Pharmaceuticals, Inc.
Company details
Developer of peptide therapeutics for the treatment of rare genetic deficiencies. It offers a lead peptide product candidate setmelanotide which is a potent, first-in-class melanocortin-4 receptor (MC4R) agonist for the treatment of Prader-Willi syndrome (PWS) and pro-opiomelanocortin deficiency obesity.
- Headquarters Boston, United States
- Employees 283
- Stage Public
- SectorsHealthcare
- Website category Health · Biotechnology and Pharmaceuticals
- Email••••••••
- Website motustx.com
- Social LinkedIn X
- Legal Name Rhythm Pharmaceuticals, Inc.
- Annual Revenue$189.76 M (USD)45.83as on Dec 31, 2025
- Net Profit-$196.54 M (USD)24.58as on Dec 31, 2025
- EBITDA-$190.68 M (USD)27.76as on Dec 31, 2025
- Total Equity Funding$84M (USD)
in 9 rounds
- Latest Funding Round$150M (USD), Post-IPO
Apr 2024
- InvestorsHHS
& 9 more
- Employee Count283
- Investments & Acquisitions
Products & Services of Rhythm Pharmaceuticals
Rhythm Pharmaceuticals offers a comprehensive portfolio of products and services, including IMCIVREE and Clinical Trials.
IMCIVREE is utilized as a treatment for rare obesity disorders associated with neuroendocrine diseases
Clinical trials are conducted by Rhythm Pharmaceuticals to advance treatments for hyperphagia and obesity
Funding Insights of Rhythm Pharmaceuticals
Rhythm Pharmaceuticals has successfully raised a total of $84M across 9 strategic funding rounds. The most recent funding activity was a Post-IPO round of $150 million completed in April 2024. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $84M
- Total Rounds 9
- Last Round Post-IPO — $150M
- First Round $21M
(Mar 2010)
- Investors Count 10
All 9 funding rounds of Rhythm Pharmaceuticals with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Apr 2024 | $150M | Post-IPO | – | – | |
| Feb 2017 | $41M | Debt – Venture | – | – | |
| Jul 2015 | $999,353 | Grant | – | – | |
| Sep 2013 | $1.4M | Grant | – | – | |
| Jul 2013 | $11M | Series B | – | – | – |
| Dec 2012 | $25M | Series B | – | – | |
| Nov 2012 | $8M | Series B | – | Pfizer Venture Investments | |
| Aug 2010 | $19M | Series A | – | Third Rock Ventures | |
| Mar 2010 | $21M | Series A | – | – |
10 investors in total: 10 institutional.
Investors in Rhythm Pharmaceuticals
Rhythm Pharmaceuticals has secured backing from 10 investors, including venture fund and institutional investors. Prominent investors backing the company include HHS, Ipsen and Orbimed.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Health-tech companies are targeted for venture capital investments. | 1999 | perceptivelife.com | New York, United States | |
Healthcare ecosystem is supported through investment and innovation by Deerfield. | deerfield.com | New York, United States | ||
Investments are made by OrbiMed in global healthcare innovations across biopharmaceuticals and related fields. | 1989 | orbimed.com | New York, United States | |
Venture capital investments are offered to startups by NEA. | nea.com | Menlo Park, United States | ||
Venture capital is focused on healthcare by Pfizer's investment arm. | pfizer.com/partnering/areas_of_interest/venture_investments | New York, United States | ||
Venture capital funding is provided to early-stage life science companies. | thirdrockventures.com | Boston, United States | ||
Biopharmaceutical company focused on developing and commercializing innovative treatments in oncology, rare disease, and neuroscience to improve patient health outcomes | 1929 | ipsen.com | ||
Invests in biotech firms developing life-saving drugs and technologies. | mpmcapital.com | |||
Public health and human services are overseen by HHS. | 1953 | hhs.gov | ||
Research for Parkinson's disease is funded by the foundation. | 2000 | michaeljfox.org | New York, United States |
Investor details for Rhythm Pharmaceuticals
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Rhythm Pharmaceuticals
83 people are tracked at Rhythm Pharmaceuticals (54 in leadership, 7 in board & advisors, 22 in team); the tracked headcount is 283.
| Name | Role | Group |
|---|---|---|
David Meeker | CEO | Leadership |
Job Den Hollander | Senior Director International Marketing | Leadership |
Jieruo Liu | Director, Value & Evidence | Leadership |
Yann Mazabraud | EVP, Head of International | Leadership |
Pam Cramer | Chief Human Resource Officer | Leadership |
Jennifer Chien | EVP, Head of North America | Leadership |
Jodi Dreiling | Director Of Medical Education | Leadership |
Ann Hnatishion | Vice President, US Sales | Leadership |
Shelina Jiwa | Marketing Director | Leadership |
Vito Lavopa | Head - Drug Substance, Technical Operations | Leadership |
Camilo R. | Vice President Market Access And External Affairs | Leadership |
Hunter Smith | CFO | Leadership |
Michalis Douramanis | IT CRM Business Support Partner, International | Leadership |
Andy Sontag | Vice President, Head Of Information Technology | Leadership |
Gauri Malthankar | Senior Medical Director, North America | Leadership |
Ali Mohamadi | Vice President, Head Of Medical Affairs North America | Leadership |
Lisa Burke | Executive Director, Global Medical Affairs | Leadership |
Ilana Koyfman | Director, Head Of Medical Information | Leadership |
Laura Katz | Senior National Director, Field Medical | Leadership |
Cory Vick Baker | Associate Director, Field Medical And Field-based Trainer | Leadership |
63 more people are available in the full profile.
Complete people profiles for Rhythm Pharmaceuticals
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
IPO & Listings of Rhythm Pharmaceuticals
Rhythm Pharmaceuticals is a publicly listed company on the NASDAQ with ticker symbol RYTM in USA, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
- IPO date05 Oct 2017
- Listed onNASDAQ: RYTM
- Listed entityRhythm Pharmaceuticals, Inc.
- Exchange sectorHealth technology
- ISINUS76243J1051
- Share price$86.61 (-3.57% on the day) · 2026-10-13
- Market capitalisation$5.96B
- EPS (diluted, trailing year)$-3.12
- Volume (last session)623,190
Financials of Rhythm Pharmaceuticals
| Year | Revenue | Net income | EBITDA |
|---|---|---|---|
| 2025 | $189.8M | -$196.5M | -$190.7M |
| 2024 | $130.1M | -$260.6M | -$263.9M |
| 2023 | $77.4M | -$184.7M | -$182.6M |
| 2022 | $23.6M | -$181.1M | -$177.8M |
| 2021 | $3.1M | -$69.6M | -$168.9M |
Detailed financial statements for Rhythm Pharmaceuticals
Statement rows, ratios, five-year trends and downloadable financials of the group companies require an active premium plan.
- Statement rows
- Financial ratios
- Five-year trends
- Downloads
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Rhythm Pharmaceuticals
Rhythm Pharmaceuticals has strategically engaged in corporate development activities, having acquired 1 company. Notable acquisitions include Xinvento.
| Company Name | Description | Domain | Location | Founded | Acquired | Amount |
|---|---|---|---|---|---|---|
Therapies for congenital hyperinsulinism are researched and developed. | xinvento.com | Amsterdam, Netherlands | 2021 | Feb 2023 | •••• |
Complete acquisition details for Rhythm Pharmaceuticals
Acquired stakes, deal sources and the complete acquisition history require an active premium plan.
- Acquired stakes
- Deal sources
- Complete history
- Exports
Verified entity values are shown only after access is granted.
Timeline of Rhythm Pharmaceuticals
5 dated milestones of Rhythm Pharmaceuticals across 14 years, from founding to its latest funding, stage changes and deals.
- Founded Rhythm Pharmaceuticals is founded.
- Funding First funding round of $21.0M.
- IPO Lists on the stock exchange (IPO).
- Acquisition Acquires Xinvento.
- Funding Latest funding round, Post-IPO, of $150.0M.
Web traffic of Rhythm Pharmaceuticals
The website of Rhythm Pharmaceuticals (rhythmtx.com) receives about 30.7K visits a month and ranks #1,305,357 among all websites worldwide, #1,678 in Biotechnology and Pharmaceuticals.
- Monthly visits30.7K
▲ 50.3% vs previous month
- Unique visitors7.5K
per month
- Global rank#1,305,357
among all websites
- Category rank#1,678
Health · Biotechnology and Pharmaceuticals
- Bounce rate43%
- Pages per visit1.9
- Average visit36 sec
- DevicesDesktop 29% · Mobile 71%
Websites whose visitors overlap most with Rhythm Pharmaceuticals. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
| avadel.com | 100% | 8K | #1,705,741 | View details | |
rythm.com | rythm.com | 63% | #611,361 | – | |
endocrine-abstracts.org | endocrine-abstracts.org | 54% | #398,762 | – |
Top companies in Metabolic Diseases
3 companies that operate in the same segment as Rhythm Pharmaceuticals (Metabolic Diseases) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Satiety induction through digestable gastric balloon introduced via a swallowed capsule | 2009 | Wellesley, Massachusetts, United States | USD 174.04 M | USD 32.11 M | 137 | |
Developer of small-molecule drugs | 1991 | Los Angeles, California, United States | USD 50 M | USD 348.97 M | 407 | |
Developer of cortisol modulators for the treatment of various diseases | 1998 | Menlo Park, California, United States | USD 761.41 M | 500 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Rhythm Pharmaceuticals
Complete news archive for Rhythm Pharmaceuticals
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Rhythm Pharmaceuticals
Rhythm Pharmaceuticals was founded in 2010.
Rhythm Pharmaceuticals is headquartered in Boston, United States. It is registered at Boston, Massachusetts, United States.
David Meeker is the CEO of Rhythm Pharmaceuticals, as recorded in our data.
Rhythm Pharmaceuticals is a funded company, having raised a total of $84M across 9 funding rounds to date. The company's 1st funding round was a Series A of $21M, raised on Mar 2010.
Rhythm Pharmaceuticals has 283 employees.
Annual revenue of Rhythm Pharmaceuticals is $189.76M as on Dec 31, 2025.
Developer of peptide therapeutics for the treatment of rare genetic deficiencies. It offers a lead peptide product candidate setmelanotide which is a potent, first-in-class melanocortin-4 receptor (MC4R) agonist for the treatment of Prader-Willi syndrome (PWS) and pro-opiomelanocortin deficiency obesity.
Rhythm Pharmaceuticals offers IMCIVREE and Clinical Trials.
Yes, Rhythm Pharmaceuticals is publicly traded on NASDAQ under the ticker symbol RYTM.
Rhythm Pharmaceuticals has made 1 acquisition, including Xinvento.
Rhythm Pharmaceuticals has 10 investors. Key investors include HHS, Ipsen, Orbimed, The Michael J. Fox Foundation, and Perceptive Advisors.
Rhythm Pharmaceuticals operates through Rhythm Pharmaceuticals, Inc.
